Angiogenesis 2024: AVD-104 for Geographic Atrophy

Carl Danzig, MD, sat down with Martin David Harp of Ophthalmology Times to discuss his presentation AVD-104 for Geographic Atrophy: Glyco-immunologic modulation of macrophage activity from the Angiogenesis Exudation and Degeneration 2024 event.

Related Videos

Related Content

Advertisement

October 24th 2024

EyePoint Pharmaceuticals announces first patient dosed in global Phase 3 LUGANO clinical trial of Duravyu for wet AMD

August 30th 2024

Latest advances in X-linked retinitis pigmentosa: Optimizing diagnosis and developments in gene therapy

October 23rd 2024

The top 10 takeaways from AAO 2024

June 20th 2024

Assessing the Evidence for Extending Treatment Intervals in nAMD & DME Management: Expert Insights into Innovative Approaches

October 22nd 2024

Ocuphire completes acquisition of Opus Genetics

October 22nd 2024

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function

Related Content

Advertisement

October 24th 2024

EyePoint Pharmaceuticals announces first patient dosed in global Phase 3 LUGANO clinical trial of Duravyu for wet AMD

August 30th 2024

Latest advances in X-linked retinitis pigmentosa: Optimizing diagnosis and developments in gene therapy

October 23rd 2024

The top 10 takeaways from AAO 2024

June 20th 2024

Assessing the Evidence for Extending Treatment Intervals in nAMD & DME Management: Expert Insights into Innovative Approaches

October 22nd 2024

Ocuphire completes acquisition of Opus Genetics

October 22nd 2024

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function